151 related articles for article (PubMed ID: 30089915)
1. Genomic prediction of relapse in recipients of allogeneic haematopoietic stem cell transplantation.
Ritari J; Hyvärinen K; Koskela S; Itälä-Remes M; Niittyvuopio R; Nihtinen A; Salmenniemi U; Putkonen M; Volin L; Kwan T; Pastinen T; Partanen J
Leukemia; 2019 Jan; 33(1):240-248. PubMed ID: 30089915
[TBL] [Abstract][Full Text] [Related]
2. Improved graft-versus-host disease-free, relapse-free survival associated with bone marrow as the stem cell source in adults.
Mehta RS; Peffault de Latour R; DeFor TE; Robin M; Lazaryan A; Xhaard A; Bejanyan N; de Fontbrune FS; Arora M; Brunstein CG; Blazar BR; Weisdorf DJ; MacMillan ML; Socie G; Holtan SG
Haematologica; 2016 Jun; 101(6):764-72. PubMed ID: 27036159
[TBL] [Abstract][Full Text] [Related]
3. Comparison of graft-versus-host disease-free, relapse-free survival according to a variety of graft sources: antithymocyte globulin and single cord blood provide favorable outcomes in some subgroups.
Inamoto Y; Kimura F; Kanda J; Sugita J; Ikegame K; Nakasone H; Nannya Y; Uchida N; Fukuda T; Yoshioka K; Ozawa Y; Kawano I; Atsuta Y; Kato K; Ichinohe T; Inoue M; Teshima T;
Haematologica; 2016 Dec; 101(12):1592-1602. PubMed ID: 27662017
[TBL] [Abstract][Full Text] [Related]
4. Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.
Faridi RM; Kemp TJ; Dharmani-Khan P; Lewis V; Tripathi G; Rajalingam R; Daly A; Berka N; Storek J; Masood Khan F
PLoS One; 2016; 11(6):e0158242. PubMed ID: 27341514
[TBL] [Abstract][Full Text] [Related]
5. Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide.
McCurdy SR; Kasamon YL; Kanakry CG; Bolaños-Meade J; Tsai HL; Showel MM; Kanakry JA; Symons HJ; Gojo I; Smith BD; Bettinotti MP; Matsui WH; Dezern AE; Huff CA; Borrello I; Pratz KW; Gladstone DE; Swinnen LJ; Brodsky RA; Levis MJ; Ambinder RF; Fuchs EJ; Rosner GL; Jones RJ; Luznik L
Haematologica; 2017 Feb; 102(2):391-400. PubMed ID: 27846611
[TBL] [Abstract][Full Text] [Related]
6. Comparable outcome after single-antigen-mismatched versus matched unrelated donor haematopoietic cell transplantation.
Rockstroh A; Al-Ali HK; Lange T; Pönisch W; Krahl R; Cross M; Behre G; Niederwieser D; Pfrepper C
J Cancer Res Clin Oncol; 2015 Dec; 141(12):2193-203. PubMed ID: 26129640
[TBL] [Abstract][Full Text] [Related]
7. Combination of low-dose mycophenolate mofetil with cyclosporine and methotrexate as GVHD prophylaxis in unrelated donor allogeneic stem cell transplantation.
Zhu X; Lai X; Luo Y; Shi J; Tan Y; Zheng W; He J; Xie W; Li L; Zhang J; Ye X; Lin M; Cai Z; Huang H
Leuk Res; 2013 Sep; 37(9):1046-51. PubMed ID: 23849987
[TBL] [Abstract][Full Text] [Related]
8. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
9. Allogeneic transplantation of G-CSF mobilized peripheral blood stem cells from unrelated donors: a retrospective analysis.
Bornhäuser M; Theuser C; Soucek S; Hölig K; Klingebiel T; Blau W; Fauser A; Runde V; Schwinger W; Rutt C; Ehninger G
Haematologica; 2000 Aug; 85(8):839-47. PubMed ID: 10942931
[TBL] [Abstract][Full Text] [Related]
10. The cell composition of infused donor lymphocyte has different impact in different types of allogeneic hematopoietic stem cell transplantation.
Zhao XS; Wang Y; Yan CH; Wang JZ; Zhang XH; Xu LP; Liu KY; Huang XJ
Clin Transplant; 2014 Aug; 28(8):926-34. PubMed ID: 24931494
[TBL] [Abstract][Full Text] [Related]
11. Similar survival following HLA-identical sibling transplantation for standard indication in children with haematologic malignancies: a single center comparison of mobilized peripheral blood stem cell with bone marrow transplantation.
Meisel R; Enczmann J; Balzer S; Bernbeck B; Kramm C; Schönberger S; Sinha K; Tröger A; Wernet P; Göbel U; Laws HJ; Dilloo D
Klin Padiatr; 2005; 217(3):135-41. PubMed ID: 15858704
[TBL] [Abstract][Full Text] [Related]
12. Partial T-cell depletion improves the composite endpoint graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic stem cell transplantation.
Simonetta F; Masouridi-Levrat S; Beauverd Y; Tsopra O; Tirefort Y; Koutsi A; Stephan C; Polchlopek-Blasiak K; Pradier A; Dantin C; Ansari M; Roosnek E; Chalandon Y
Leuk Lymphoma; 2018 Mar; 59(3):590-600. PubMed ID: 28679328
[TBL] [Abstract][Full Text] [Related]
13. Reduced intensity haplo plus single cord transplant compared to double cord transplant: improved engraftment and graft-versus-host disease-free, relapse-free survival.
van Besien K; Hari P; Zhang MJ; Liu HT; Stock W; Godley L; Odenike O; Larson R; Bishop M; Wickrema A; Gergis U; Mayer S; Shore T; Tsai S; Rhodes J; Cushing MM; Korman S; Artz A
Haematologica; 2016 May; 101(5):634-43. PubMed ID: 26869630
[TBL] [Abstract][Full Text] [Related]
14. [Analysis of risk factors for relapse of 82 patients with hematologic malignancies after allogeneic hematopoietic stem cell transplantation].
Yu ZP; Ding JH; Chen BA; Wu F; Gao C; Sun YY; Chen J; Zhao G; Wang J; Li YF; Ding BH; Qian J
Zhonghua Zhong Liu Za Zhi; 2011 Apr; 33(4):283-6. PubMed ID: 21575500
[TBL] [Abstract][Full Text] [Related]
15. TNF polymorphisms are associated with toxic but not with aGVHD complications in the recipients of allogeneic sibling haematopoietic stem cell transplantation.
Bogunia-Kubik K; Polak M; Lange A
Bone Marrow Transplant; 2003 Sep; 32(6):617-22. PubMed ID: 12953135
[TBL] [Abstract][Full Text] [Related]
16. Donor Genotype in the Interleukin-7 Receptor α-Chain Predicts Risk of Graft-versus-Host Disease and Cytomegalovirus Infection after Allogeneic Hematopoietic Stem Cell Transplantation.
Kielsen K; Enevold C; Heilmann C; Sengeløv H; Pedersen AE; Ryder LP; Müller K
Front Immunol; 2018; 9():109. PubMed ID: 29456530
[TBL] [Abstract][Full Text] [Related]
17. Both genetic and clinical factors predict the development of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
Socié G; Loiseau P; Tamouza R; Janin A; Busson M; Gluckman E; Charron D
Transplantation; 2001 Aug; 72(4):699-706. PubMed ID: 11544434
[TBL] [Abstract][Full Text] [Related]
18. Primary graft failure after myeloablative allogeneic hematopoietic cell transplantation for hematologic malignancies.
Olsson RF; Logan BR; Chaudhury S; Zhu X; Akpek G; Bolwell BJ; Bredeson CN; Dvorak CC; Gupta V; Ho VT; Lazarus HM; Marks DI; Ringdén OT; Pasquini MC; Schriber JR; Cooke KR
Leukemia; 2015 Aug; 29(8):1754-62. PubMed ID: 25772027
[TBL] [Abstract][Full Text] [Related]
19. Outcomes after Second Hematopoietic Stem Cell Transplantations in Pediatric Patients with Relapsed Hematological Malignancies.
Naik S; Martinez C; Leung K; Sasa G; Nguyen NY; Wu MF; Gottschalk S; Brenner M; Heslop H; Krance R
Biol Blood Marrow Transplant; 2015 Jul; 21(7):1266-72. PubMed ID: 25765555
[TBL] [Abstract][Full Text] [Related]
20. Systemic biomarkers of allogeneic haematopoietic stem cell transplantation outcome-Brief introduction.
Mrazek F
HLA; 2019 Dec; 94 Suppl 2():25-29. PubMed ID: 31729192
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
